Jun 14, 2023 / 10:20PM GMT
Chris Shibutani - Goldman Sachs Group, Inc., Research Division - Research Analyst
Okay, and welcome to the Wednesday afternoon session. It's Wednesday, right? Yes. My name is Chris Shibutani, a member of the research team, along with my associates. We are very excited to have Kymera join us this year for the 44th Annual Goldman Sachs Healthcare Conference.
Here we have on the podium with me, Nello Mainolfi, Founder, President and CEO, lots of titles here. And then hidden off in the audience, Bruce Jacobs, the Chief Financial Officer. Bruce, we see you. You can only hide so long. The team that's out here, obviously, is coming at this meeting at an exciting time. There's folks. Jared, you're -- Gollob, you're their Chief Medical Officer, is very busy at some medical meetings because you guys have been super busy, a lot of progress points.
We want to make sure that we talk about some of the data reveals and new information that we've had today. And I did also want to just make sure that we talked about sort of like the partnership communications because, especially at this event, there has
Kymera Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot